Nails are protective structures made of hard keratin. The main characteristic of a healthy nail is hardness.

Rosacea is one of our key innovation areas. It is a chronic inflammatory disease, mainly affecting facial skin, however the burden of rosacea goes far beyond this. Results from our global survey highlight the individual characteristics and challenges of living with this disease. Read the full report here: https://bit.ly/2H8w5z4 #rosacea

Our employees in Fort Worth, Texas, really know how to give back! These gifts are being packaged up this week to ship out to 88 Camp Wonder kids for our 4th annual Angel Tree drive supporting The Children's Skin Disease Foundation.

At least 3,000 skin diseases are thought to exist. Atopic dermatitis is one of them. It is also one of our key therapeutic areas. #atopicdermatitis

To help advance the growing #SkinMicrobiome field, our SHIELD Center is hosting its first-ever Skin Microbiome Summit on March 6th, 2019. This summit will convene industry and clinical experts who will discuss important trends, emerging research and the latest innovations in the Skin Microbiome space.

Delighted that Dr. Paul Schilf from the Lübeck Institute for Experimental Dermatology has been awarded the 2018 Theodor-Nasemann scholarship from Galderma. A grant of €10,000 will help Dr. Schilf further research microbiome-host interactions and their influence on skin health. #dermatology #research

Psoriasis is a chronic inflammatory skin disease usually genetically predisposed.

The Galderma Skinpact Awards aim to inspire dermatologists, healthcare professionals and scientific societies to develop and help implement projects that advance dermatology. The international dermatology community is invited to vote for their preferred shortlisted projects from the 2018 edition https://lnkd.in/gQJXAsA #dermatology

We are pleased to share that Galderma has won 3 awards at the 15th Philippine Academy of Clinical and Cosmetic Dermatology Convention in Manila including the Doctor’s Choice Award voted by the 450 dermatologists in attendance!

Today we announced positive results from a Phase 2b dose-ranging study of nemolizumab in adult patients with moderate-to-severe atopic dermatitis, a serious, chronic form of eczema.